|
Species | Carbohydrate antigen | Name of antibody | Peptide library | Peptide motif or representative sequences (peptide name) | References | Notes* |
|
Cryptococcus neoformans | Polysaccharide (glucuronoxylomannan; GXM) | 2H1 | X6, X10, ADVA X6 TPXW [M/L][M/L] X6 AAG | (E)TPXWM/LM/L, W/YXWM/LY; GLQYTPSWMLVG (PA1); SYSWMYE (P601E); FGGETFTPDWMMEVAIDNE (P206.1) | [64–67] | Four motifs; X-ray analysis (PA1); peptide evolution (P206.1); peptide-KLH/TT |
Streptococcus species | Capsular polysaccharide (type 3, group B) | S9 | X9 | WENWMMGNA; FDTGAFDPDWPA | [68] | Group B streptococci (GBS); peptide-KLH/BSA/OVA |
Streptococcus pneumoniae | Capsular polysaccharide (serotype 4) | mAb4 | X15 | SGQARVLYSEFINAL (pep4) | [69] | DNA vaccine |
(serotype 8) | (human mAb IgA) | X12 | FHLPYNHNWFAL (PUB1) | [70] | Peptide-TT |
(serotype 6B, 9V) | 206; F-5; Db3G9 | X12, X15 | MP7, 12, 55, 58 | [71] | Peptide-KLH |
Streptococcus pyogenes | Cell-wall polysaccharide (group A) | SA-3; Strep9; HGAC39; HGAC47; HGAC101 | X6, XCX8CX, X8CX8, X15CX, X15 | DRPVPY | [72] | Basis of peptide-carbohydrate cross-reactivity |
Streptococcus agalactiae | (serotype A, B, C) | (IgG2, Ig polyclonal) | X12 | NPDHPRVPTFMA (2–8); LIPFHKHPHHRG (3-2) | [73] | DNA vaccine; MAP-CFA/IFA |
Neisseria meningitidis | Capsular polysaccharide (serogroup A) | 9C10 | X15 | GEASGLCCRWSSLKGC | [74] | Peptide-proteasome |
(serogroup B) | HmenB3 | X12 | NKVIWDRDWMYP | [75] | Peptide-BSA-CFA/IFA |
(serogroup B) | 9-2-L3, 7, 9 | CX6C, CX9C | CGAVIDDC | [76] | Peptide-KLH |
(serogroup B) [poly-2–8 sialic acid (PSA)] | 30H12 | CX9C | CSSVTAWTTGCG | [77, 78] | Enhanced migration of grafted neuroblasts in mouse brain |
(serogroup B) | Seam3 | X9, X12 | DYAWDQTHQDPAK (9M) | [79] | Peptide-KLH, DNA vaccine |
(serogroup B) | 13D9 | X15 | RGDKSRPPVWYVEGE | [80] | Phage vaccine |
(serogroups B and C) | (IgG2, Ig polyclonal) | X12 | EQEIFTNITDRV (G3) | [73] | DNA vaccine; MAP-CFA/IFA |
(serogroup C) | 1E4 | X15 | GFSYYRPPWIL (Pep2C) | [81] | Peptide-proteasome |
[N-propionyl derivative of CPS] | — | — | — | [82] | |
Vibrio cholerae | Capsular polysaccharide (serogroup O139) | Vc1; Vc2; ICL12 | six libraries (X9, X12, X28 etc.) | AEGEFSPGVWKAAFQGDKLPDPAK and so forth | [83] | Peptide-KLH/BSA |
(serogroup O1) Ogawa serotype | S-20-4; A-20-6 | X12, X7, CX7C | NHNYPPLSLLTF (4P-8) | [84] | Peptide-KLH/BSA; docking study |
(serogroup O1) Ogawa and Inab serotypes | 72.1 | X12, X7, CX7C | ECLLLSKYCMPS (3ME-1); SMCMHGGAYCFP (3ME-2) | [85] | Peptide-KLH/BSA-CFA/IFA |
Shigella flexneri | O-antigen of lipopolysaccharide (serotype 5a) | mIgAs C5; I3 | X9 | YKPLGALTH; KVPPWARTA | [86] | Phage vaccine |
(serotype 2a) | F22-4 | X12 | YLEDWIKYNNQK (B1) | [19] | X-ray analysis |
— | Melanoma-associated chondroitin sulfate proteoglycan (MCSP) | 763.74 | X6 | VHINAH | [87] | Inhibition of MCSP binding |
Entamoeba histolytica | GPI-linked proteophosphoglycan antigens | EH5 | six libraries (X9, X12, X28 etc.) | GTHPXL | [88] | Glycosylphosphatidylinositol (GPI); phage vaccine |
Mycobacterium tuberculosis | Neutral polysaccharides | — | X12 | QEPLMGTVPIRAGGGS (P1) | [89] | Peptide oligomer vaccine |
Mycobacterium tuberculosis | Mannosylated lipoarabinomannan | CS40 | X12 | ISLTEWSMWYRH (B11) | [90] | Peptide-KLH-adjuvants |
Burkholderia pseudomallei | Exopolysaccharide (EPS) | 3VIE5; 4VA5 | X12, X7, CX7C | CYLPFQLSC; CHPLFDARC | [91] | Peptide-thyroglobulin |
Brucella melitensis; Brucella abortus | Lipopolysaccharide | 4F9; 11B2 | X9, X12, CX9CX, X15 | WTEIHDWEAAME | [92] | DNA vaccine |
Staphylococcus aureus | Peptidoglycan | — | X12 | Sp-31 | [93] | MAP vaccine |
|